In the arena of treating invasive group A streptococcal (GAS) infection in adults, linezolid is emerging as a promising alternative for adjunctive antitoxin therapy. This is based on the findings from a large scale, multicenter, retrospective non-inferiority study of adult inpatients, published in The Lancet Infectious Diseases.
Conducted from 2016 to 2021, the study offers…